3.215.190.193
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Oculoplastics

Majority of proptosis responders maintain long-term response with teprotumumab

Posted on

Results from a study to assess long-term proptosis response and diplopia grade in patients treated with teprotumumab (Tepezza, Horizon) for thyroid eye disease (TED), demonstrated that the majority of teprotumumab-treated patients maintained improvements 51 weeks after the last dose, similar to the phase 2 study, according to an on-demand video presentation at 2020 AAO Virtual.

Teprotumumab, a fully human monoclonal antibody inhibitor of insulin-like growth factor-1 receptor (IGF-1R), is indicated for the treatment of TED, a progressive and vision-threatening rare autoimmune disease.

For the OPTIC study, patients were followed for 48 weeks after the 24-week study (final infusion at Week 21) for maintenance of response off treatment to Week 72. Results at Week 24 showed that 83% (34/41) of patients had a ≥2 mm proptosis reduction and 68% (19/28) had a ≥1 grade diplopia improvement (16/28 with score of 0) in the teprotumumab arm. Of these 24-week responders, 56% (19/34) maintained proptosis response, while 58% (11/19) maintained ≥1 grade diplopia improvement and 50% (8/16) maintained a diplopia score of 0 at Week 72. There were no new safety concerns in the OPTIC follow-up period.

OPTIC-X data provide evidence supporting the use of teprotumumab in patients who have had TED for a longer period of time than what was originally studied in the phase 2 and phase 3 clinical trials (up to 16 months vs an average of 6 months in OPTIC). The OPTIC-X extension trial will continue to evaluate treatment response.

Reference
Douglas RS, et al. Long-term assessment of proptosis and diplopia from the OPTIC trial of teprotumumab in thyroid eye disease. Presented at: AAO 2020 Virtual [Session: PA038.01]

 

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
More research needed on link between strabismus and mental health disorders in kids
May 21, 2021
Patient demographics influence utilization of care for eye conditions
May 21, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-